This article is a correction to:
Safety of Semaglutide
Mark M. Smits
Daniël H. Van Raalte- Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands
A Corrigendum on
Safety of Semaglutide
By Smits MM and Van Raalte DH (2021) Front. Endocrinol. 12:645563. doi: 10.3389/fendo.2021.645563
In the original article, there was a mistake in Table 2. Adverse effects and safety risks in phase 3 trials as published. Three values in the row for SUSTAIN 6, s.c semaglutide 1 mg were accidentally transposed to the incorrect column. The corrected Table 2 appears below.
TABLE 2
Table 2 Adverse effects and safety risks in phase 3 trials (10–32).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: glucagon-like peptide-1 receptor agonist (GLP-1RA), oral, subcutaneous, semaglutide, type 2 diabetes, safety
Citation: Smits MM and Van Raalte DH (2021) Corrigendum: Safety of Semaglutide. Front. Endocrinol. 12:786732. doi: 10.3389/fendo.2021.786732
Received: 30 September 2021; Accepted: 15 October 2021;
Published: 10 November 2021.
Edited by:
Francesco Giorgino, University of Bari Aldo Moro, ItalyReviewed by:
Stephen Bain, Swansea University, United KingdomCopyright © 2021 Smits and Van Raalte. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Daniël H. Van Raalte, ZC52YW5yYWFsdGVAYW1zdGVyZGFtdW1jLm5s